Genetic Etiologies for Chronic Kidney Disease Revealed through Next-Generation Renal Gene Panel.


Journal

American journal of nephrology
ISSN: 1421-9670
Titre abrégé: Am J Nephrol
Pays: Switzerland
ID NLM: 8109361

Informations de publication

Date de publication:
2022
Historique:
received: 23 11 2021
accepted: 17 01 2022
pubmed: 25 3 2022
medline: 14 5 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

Chronic kidney disease (CKD) is a major public health issue in the USA. Identification of monogenic causes of CKD, which are present in ∼10% of adult cases, can impact prognosis and patient management. Broad gene panels can provide unbiased testing approaches, which are advantageous in phenotypically heterogeneous diseases. However, the use and yield of broad genetic panels by nephrologists in clinical practice is not yet well characterized. Renal genetic testing, ordered exclusively for clinical purposes, predominantly by general and transplant nephrologists within the USA, was performed on 1,007 consecutive unique patient samples. Testing was performed using a commercially available next-generation sequencing-based 382 gene kidney disease panel. Pathogenic (P) and likely pathogenic (LP) variants were reported. Positive findings included a monoallelic P/LP variant in an autosomal dominant or X-linked gene and biallelic P/LP variants in autosomal recessive genes. Positive genetic findings were identified in 21.1% (212/1,007) of cases. A total of 220 positive results were identified across 48 genes. Positive results occurred most frequently in the PKD1 (34.1%), COL4A5 (10.9%), PKD2 (10.0%), COL4A4 (6.4%), COL4A3 (5.9%), and TTR (4.1%) genes. Variants identified in the remaining 42 genes comprised 28.6% of the total positive findings, including single positive results in 26 genes. Positive results in >1 gene were identified in 7.5% (16/212) of cases. Use of broad panel genetic testing by clinical nephrologists had a high success rate, similar to results obtained by academic centers specializing in genetics.

Identifiants

pubmed: 35325889
pii: 000522226
doi: 10.1159/000522226
pmc: PMC9216312
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

297-306

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Références

J Am Soc Nephrol. 2016 Mar;27(3):942-51
pubmed: 26150605
Am J Kidney Dis. 2016 Dec;68(6):862-872
pubmed: 27578184
N Engl J Med. 2019 Jan 10;380(2):142-151
pubmed: 30586318
Kidney Int. 2019 Apr;95(4):914-928
pubmed: 30773290
Ann Intern Med. 2018 Jan 16;168(2):100-109
pubmed: 29204651
Hum Genet. 2021 Mar;140(3):477-492
pubmed: 32915251
Eur J Hum Genet. 2021 Aug;29(8):1186-1197
pubmed: 33854215
Clin J Am Soc Nephrol. 2012 Aug;7(8):1337-46
pubmed: 22537653
Nat Rev Dis Primers. 2019 Sep 5;5(1):60
pubmed: 31488840
Kidney Med. 2021 Oct 05;3(6):1050-1056
pubmed: 34939014
Nephrol Dial Transplant. 2022 Jan 25;37(2):349-357
pubmed: 33306124
J Am Soc Nephrol. 2020 Feb;31(2):393-404
pubmed: 31810990
J Am Soc Nephrol. 2018 Oct;29(10):2458-2470
pubmed: 30228150
J Am Soc Nephrol. 2013 Sep;24(9):1484-91
pubmed: 23766536
N Engl J Med. 1997 Feb 13;336(7):466-73
pubmed: 9017939
Pediatr Nephrol. 2019 Sep;34(9):1607-1613
pubmed: 31001663
Am J Nephrol. 2020;51(1):43-53
pubmed: 31822006
Genet Med. 2021 Jan;23(1):183-191
pubmed: 32939031
Kidney Int Rep. 2020 Nov 10;6(2):272-283
pubmed: 33615052
Nephrol Dial Transplant. 2021 Jan 25;36(2):295-305
pubmed: 31738409
Kidney Med. 2020 Aug 07;2(5):639-649
pubmed: 33094278
JAMA. 2014 Nov 26;312(20):2115-25
pubmed: 25393378
J Clin Invest. 2020 Jan 2;130(1):335-344
pubmed: 31613795
J Am Soc Nephrol. 2017 Jul;28(7):2180-2187
pubmed: 28280138
Genet Med. 2020 Jan;22(1):142-149
pubmed: 31337885
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Eur J Hum Genet. 2021 May;29(5):760-770
pubmed: 33437033
Kidney Int. 2018 May;93(5):1045-1051
pubmed: 29551517
Genet Med. 2021 Jul;23(7):1219-1224
pubmed: 33712733
Nat Rev Nephrol. 2019 Jun;15(6):321-322
pubmed: 30903026
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669

Auteurs

Anthony J Bleyer (AJ)

Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Maggie Westemeyer (M)

Natera, Inc., San Carlos, California, USA.

Jing Xie (J)

Natera, Inc., San Carlos, California, USA.

Michelle S Bloom (MS)

Natera, Inc., San Carlos, California, USA, mbloom@natera.com.

Katya Brossart (K)

Natera, Inc., San Carlos, California, USA.

Jason J Eckel (JJ)

North Carolina Nephrology Associates, Cary, North Carolina, USA.

Frederick Jones (F)

North Carolina Nephrology Associates, Cary, North Carolina, USA.

Miklos Z Molnar (MZ)

Division of Nephrology & Hypertension, Department of Medicine, University of Utah, Salt Lake City, Utah, USA.

Wayne Kotzker (W)

Florida Kidney Physicians, Boca Raton, Florida, USA.

Prince Anand (P)

MUSC Lancaster, Lancaster, South Carolina, USA.

Stanislav Kmoch (S)

Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University, Prague, Czechia.

Yuan Xue (Y)

Fulgent Genetics, Temple City, California, USA.

Samuel Strom (S)

Fulgent Genetics, Temple City, California, USA.

Sumit Punj (S)

Natera, Inc., San Carlos, California, USA.

Zachary P Demko (ZP)

Natera, Inc., San Carlos, California, USA.

Hossein Tabriziani (H)

Natera, Inc., San Carlos, California, USA.

Paul R Billings (PR)

Natera, Inc., San Carlos, California, USA.

Trudy McKanna (T)

Natera, Inc., San Carlos, California, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH